The results (Table 2) demonstrated that disease stage pretransplant (>CR1 vs. CR1), pre-MRD (pos vs. neg), FLT3-ITD (high ratio vs. neg or low ratio), TP53 mutation (pos vs. neg), and cytogenetic classification (adverse vs. intermediate vs. favorable) were independent risk factors for AML recurrence after allo-HSCT (p < 0.05). Here, TP53 is linked to acute myeloid leukemia.